113 Impact of Preoperative GLP-1 Agonist Use on Postoperative Outcomes in Bariatric Surgery Patients: A Retrospective Cohort Study

Abstract Aim The aim of the study was to evaluate the impact of preoperative GLP-1 agonist medication on postoperative weight-loss outcomes during the first 12 months after bariatric surgery. Method A retrospective, single-centre, cohort study was conducted. A total of 85 adult patients, who underwent primary bariatric surgery (Sleeve Gastrectomy, Roux-en-Y Gastric Bypass, Mini Gastric Bypass) between January and December 2023 and were started on GLP-1 agonists six months before surgery, were included. Patients were grouped based on preoperative use (n=36) or non-use (n=49) of GLP-1 agonists. Primary outcome assessed was the percentage of excess weight loss (%EWL) at 12 months post operative. Statistical analysis was performed using the Mann-Whitney U test. Results Patients using GLP-1 agonists demonstrated significantly greater preoperative excess body weight loss compared to non-users (12.64% vs 6.95%, p=0.015). However, at 12 months postoperative, no significant statistical differences in % EWL between groups, Sleeve Gastrectomy (55.6% vs 48.1%, p=0.148), Mini Gastric Bypass (53.53% vs 51.51%, p=0.356), or Roux-en-Y Gastric Bypass (61.9% vs 56.02%, p=0.148), was noted. Conclusions Although preoperative use of GLP-1 agonists offers in improved weight reduction in preoperative time, but it did not demonstrate any superior short term postoperative weight loss outcomes for bariatric surgery patients. A multi-centre, prospective study having larger sample size with long term follow up may be required to establish and measure long-term implications.